EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
J. Guillermo Paez, Pasi Antero Janne, Jeffrey C. Lee, Sean I. Tracy, Heidi E. Greulich, Stacey Gabriel, Paula K. Herman, Frederic J. Kaye, Neal Ian Lindeman, Titus J. Boggon, Katsuhiko Naoki, Hidefumi Sasaki, Yoshitaka Fujii, Michael J. Eck, William R. Sellers, Bruce Evan Johnson, Matthew M. Meyerson
Science · 2004 · 9,452 citations
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S. I., Greulich, H. E., Gabriel, S., Herman, P. K., Kaye, F. J., Lindeman, N. I., Boggon, T. J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M. J., Sellers, W. R., Johnson, B. E., & Meyerson, M. M. (2004). EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science, 304(5676), 1497–1500. https://doi.org/10.1126/science.1099314
In text: (Paez et al., 2004)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan. EGFR mutations were found in additional lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. These results suggest that EGFR mutations may predict sensitivity to gefitinib.
Related papers
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene1987
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER22001
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib2004
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer1989
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer2017
Metadata from OpenAlex (CC0). Citations are generated from the published record.